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Background: DJ-1 is a key regulator in human tumorigenesis, including brain malignancies. The mechanisms by
which DJ-1 contributes to the pathogenesis of medulloblastoma (MB) remain unclear, and its impact on the
prognosis for patients with MB has not been identified. The aim of this study was to determine whether the
DJ-1 protein is associated with tumorigenesis of MBs, and whether DJ-1 is a valuable factor for predicting the
prognosis of patients with MB.
Methods: We collected 66 pairs of MB and adjacent normal cerebellum samples. Expression of DJ-1,
Ser 473-phosphorylated-Akt (p-Akt), PTEN, and Ki-67 (MIB-1) was detected by immunohistochemical staining,
and the correlation of these immunostaining results with the clinicopathological features of patients with MB
was determined.
Results: High DJ-1 expression (48.5%, 32/66) in tumor cells of MBs was significantly associated with the classic
MB variant (P = 0.003), high proliferative activity (P = 0.002) and undifferentiated tumor (P = 0.001), whereas
high p-Akt expression (56.1%, 37/66) was associated with tumor metastasis stage (P = 0.007), undifferentiated
tumor (P = 0.007), and high-risk tumor (P = 0.002). High DJ-1 expression also correlated with high p-Akt expression
and high MIB-1 index. However, only high levels of DJ-1(P = 0.009) and high MIB-1 index (P = 0.001) were strong
independent prognostic factors associated with worse overall survival.
Conclusions: Although the validity of the preliminary data in this study needs to be confirmed by a larger
number of cases, our study indicates that DJ-1, PTEN, and p-Akt might play important roles in cell proliferation
and differentiation of MBs. The evaluation of expression of DJ-1 and related proteins might be useful for predicting
the prognosis of patients with MB.
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Medulloblastoma (MB) is the most common malignant
tumor of central nervous system in children [1], while it
rarely occurs in adults [2]. Although multimodality treat-
ment regimens, including surgery, radiotherapy (RT), and
chemotherapy, have greatly improved disease outcome,
about one-third of patients with MB remain incurable.
Moreover, the 5-year disease survival rate is only 36% for
patients with MB with tumor dissemination and recur-
rence [3,4]. The accumulated studies in MB have come to
a consensus that MB can be classified into four core* Correspondence: lizhi@mail.sysu.edu.cn
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unless otherwise stated.subgroups: WNT (Wingless), SHH (Sonic hedgehog),
Group 3, and Group 4 [5]. Each of these subtypes has
a distinct molecular profile and genomic defects, which
are associated with varied clinical parameters and patient
outcomes. However, despite extensive investigation, the
mechanism underlying MB progression has not been fully
elucidated. More precise prognostic predictors and more
effective therapies for MBs are therefore required.
Recently, research evidence has suggested that DJ-1
plays a role in human tumorigenesis. DJ-1 is a 189
amino acid protein, and was originally identified as an
oncogene that, in combination with H-RAS, can trans-
form mouse NIH3T3 cells [6]. The DJ-1 protein has
been found in various malignant tumor cells, including
prostate cancer, non-small cell lung cancer, laryngeal cancer,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in increasing cell proliferation and metastasis [7-10]. How-
ever, the effect of DJ-1 on the development and progression
of MB has not yet been investigated.
DJ-1 is considered to contribute to oncogenesis by
upregulating protein kinase B (PKB/Akt)-mediated cell
survival [6,11]. Akt is a 57-kDa serine/threonine kin-
ase, and is a central mediator involved in the signal
transduction of various growth-controlling pathways
that involve phosphatidylinositol 3′-kinase (PI3K). PI3K,
activated by growth factors, catalyzes the phosphorylation
of phosphatidylinositol (4,5)-biphosphate (PIP2) to phos-
phatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 in turn
recruits 3-phosphoinositide-dependent kinase (PDK), which
phosphorylates and activates Akt [12]. Phosphorylated Akt
(p-Akt) plays a key role in multiple signaling pathways, in-
cluding cell proliferation, apoptosis, and transcription [13].
Basic research has demonstrated that DJ-1 could antagonize
the tumor suppressor PTEN to inhibit the activity of the
PTEN gene and finally promote the proliferation of tumor
cells [11]. PTEN is a key negative regulator of the PI3K-
protein kinase B signaling pathway. In MBs, loss of hetero-
zygosity of chromosome 10q is frequent at the position
where PTEN is located (10q23.31) [14,15]. Dysregulation of
PTEN was found to contribute to overactivation of the
PI3K/Akt signaling pathway [16,17]. Thus, we hypothesized
that DJ-1 might contribute to the progression of MB by
regulating the PTEN and Akt pathways. However, we could
not find any report about the relationship between DJ-1 and
tumorigenesis of MBs, or the mechanisms involved.
In this study, we first examined the DJ-1, PTEN, and
p-Akt expression in surgical MB tissue specimens and
paired tumor-adjacent tissue specimens. The aim of this
study was to determine whether the DJ-1 protein is asso-
ciated with tumorigenesis of MBs, and if it would be a
valuable factor for predicting the prognosis of patients
with MB.
Methods
Patients and clinical management
In retrospective study, we examined 66 pairs of paraffin
wax-embedded MB and adjacent normal cerebellum
samples collected from the Pathology Department of
the First Affiliated Hospital of Sun Yat-sen University
and Tongjiang Hospital of Guangdong during the period
of 2003 to 2012. None of the patients had received
chemotherapy or RT before surgical treatment. All experi-
mental protocols were carried out with the approval of the
Committee on Use of Human & Animal Subjects in
Teaching and Research of Sun Yat-sen University, ac-
cording to the Helsinki Declaration.
All patients had undergone midline suboccipital cra-
niectomy to resect the tumor completely or partially. Ex-
tent of resection was defined on the basis of surgicalreports and/or postoperative images. Patients received
different treatment protocols after surgery, based on age
stratification. All patients under 3 years of age received
chemotherapy after surgery with standard regimens con-
sisting of six course of temozolomide, vincristine, and
cisplatin. Patients aged over 3 years initially received RT.
Postoperative RT was conducted using craniospinal ir-
radiation (CSI), with a subsequent boost to the posterior
fossa. Patients received a total dose ranging from 40 to
54 Gy. After RT, six courses of standard chemotherapy
with temozolomide, vincristine, and cisplatin were also
used for these patients. Imaging inspection was repeated
at intervals of 3 to 6 months to evaluate treatment re-
sponse, metastasis, and tumor recurrence. All 66 patients
were given a follow-up investigation, and follow-up was
terminated in March 2013.
Histopathological subtype
All the samples were re-evaluated according to the cri-
teria of the WHO classification [18] by two experienced
pathologists, with differences resolved by careful discus-
sion. Of the 66 case of MB, 50 (75.7%) were classified
as classic MB, 14 (21.2%) as the desmoplastic variant,
1 (1.5%) as the large cell/anaplastic variant, and 1 as
MB with myogenic differentiation (previously termed
medullomyoblastoma).
Immunohistochemical staining and scoring
Serial sections 4 μm thick were cut from eah tissue block
and mounted on aminopropyltriethoxysilane (APES)-coated
glass slides. After routine preparation of slides, the sections
were incubated with one of the following antibodies: rabbit
anti-human monoclonal PTEN antibody (1:100 dilution;
D4.3), p-Akt (Ser 473) rabbit monoclonal antibody (1:25;
D9E) (both Cell Signaling technology, MA, USA), rabbit
anti-human polyclonal DJ-1 antibody (1:100; FL-189; Santa
Cruz Biotechnology, SantaCruz, CA, USA), or Ki-67 (1:100
dilution; MIB-1; Dako Co., Glostrup, Denmark) for 60 min,
respectively. Slides were processed using a ChemMate Envi-
sion/horseradish peroxidase kit (Dako) for 30 min at room
temperature, followed by development with diaminobenzi-
dine (DAB) for visualization. Positive controls consisted of
biopsies of prostate tissue containing carcinoma and normal
parenchyma (for DJ-1 and PTEN) and breast cancer (p-Akt).
Negative controls were prepared by substituting non-
immune serum for primary antibodies.
Immunohistochemical staining evaluation was conducted
as described previously [19]. Scoring of the percentage of
immunoreactive tumor cells was as follows: 0 (0%), 1 (1 to
10%), 2 (11 to 50%), and 3 (>50%). The staining intensity
was visually scored and stratified as 0 (negative), 1 (weak), 2
(moderate), and 3 (strong). A final immunoreactivity score
was obtained for each case by multiplying the percentage
and the intensity score. The median score was 4.5. Thus,
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ther classified as lower (when the score was less than 4.5)
and higher (when it was greater than 4.5). In order to re-
duce variation, all immunohistochemical staining was sep-
arately evaluated and scored semiquantitatively by two
pathologists without knowledge of the clinical data of pa-
tients. The final score for protein expression in each case
was the mean of the scores given by the two observers.
The proliferative activity of tumor cells was evaluated
by counting the Ki-67 (MIB-1) labeling index with image
analysis (Olympus Cell D1; Soft Imaging System GmbH,
Munster, Germany) counting at least 1000 tumor cells at
high magnification (×40 objective) in fields with the lar-
gest number of positive cells. Tissues were considered to
have a high MIB-1 index (MI) when the Ki-67 labeling
value was greater than the mean Ki-67 labeling value of
all 66 MBs.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 14.0 for Windows; SPSS Inc., Chicago, IL, USA).
Qualitative data are presented as number and percent.
The χ2 was used for comparison between groups, and
P < 0.05 was considered significant. Overall survival (OS)
was counted (months) from the date of diagnosis to the
date of death or last follow-up before study closure.
Kaplan-Meier method and Cox regression were used for
survival analysis.
Ethics committee approval and patient consent
This study was approved by Sun Yat-sen University review
board or ethics committee.
Results and discussion
DJ-1, p-Akt, and PTEN expression in MBs
All 66 MB samples showed detectable levels of DJ-1 and
p-Akt in tumor cells with variations in positive percent-
age and intensity (Figure 1). However, DJ-1 and p-Akt
expression was not present in adjacent normal cerebellar
tissue. The areas with high DJ-1 expression were observed
to almost overlap with those with p-Akt high expression.
Proliferative activity was particularly prominent in areas
with high expression of DJ-1 or p-Akt, which were 8.5%Figure 1 Expression levels of DJ-1 and p-Akt in tumor cells with varyi
expression of DJ-1 are shown on the left side, and high and low expression(32/66) and 56.1% (37/66), respectively. In the desmoplas-
tic variant MBs, DJ-1 and p-Akt showed a staining pat-
tern, in which the internodular (undifferentiated or poorly
differentiated) areas had higher expression than the intra-
nodular (neuronal differentiated) regions (Figure 2a, b).
PTEN expression was observed in normal cerebellum, in-
cluding the molecular layer and inner granule cell layer.
However, PTEN protein level was significantly decreased
in tumor cells, and low expression of PTEN was seen in
all MB samples. We found that 84.8% (56/66) of samples,
including all the classic MBs and four of the desmoplastic
variant samples, showed no detectable or only weak levels
of PTEN in tumor cells. A focal immunopositive PTEN
signal was observed in the intranodular regions of the
other 10 desmoplastic variant MBs (Figure 2c). In addition,
the areas with high expression of p-Akt coincided with the
regions with loss of PTEN expression.
Correlation of DJ-1, p-Akt, and PTEN expression with the
clinicopathological characteristics of medulloblastoma
We found statistically significant correlations of high
DJ-1 protein expression with slightly older children and
adults. Although MB is the most common in children, it
rarely occurs in adults. In this study, several adult patients
were collected and stratified into the study group of pa-
tient more than 3 years old. (P = 0.030), classic variant
MBs (P = 0.003), high proliferative activity (P = 0.002),
undifferentiated tumor (P = 0.001), and high-risk tumor
(P = 0.031). High p-Akt expression was also associated
with tumor metastatic stage (P = 0.007), undifferentiated
tumor (P = 0.007), and high-risk tumor (P = 0.002). High
p-Akt expression also correlated with high DJ-1 expres-
sion in tumor cells (P = 0.010). However, the expression
levels of these proteins were not statistically associated
with sex, tumor location, or size of residual tumor
(Table 1).
Prognostic relevance of DJ-1 and p-Akt expression in MBs
The follow-up time for the 66 patients with MB was 2–59
months. The most recent follow-up showed that 40 patients
were still alive, and the 5-year OS was approximately 60.6%.
Kaplan-Meier survival analysis revealed that patients with
MB with high DJ-1 expression had poorer OS than thoseng levels of positive percentage and intensity. High and low
of p-Akt on the right side. (Original magnification × 400).
Figure 2 Immunohistochemical analysis of DJ-1, PTEN, p-Akt, and Ki-67 expressionin MBs. (a) In classic MBs, DJ-1 and p-Akt appeared to
have diffused positive signal in tumor cells, but PTEN was negative in most cases. Proliferative activity (Ki-67 labeling) was particularly prominent
in areas with high expression of DJ-1 and p-Akt. (b) In desmoplastic MBs, high expression of DJ-1, p-Akt, and Ki-67 was observed in internodular
areas with undifferentiated or poorly differentiated tumor cells; however, detectable signals of PTEN were observed in intranodular areas with
neuronal differentiation. (c) Immunohistochemical analysis showed that expression of DJ-1 was significantly higher in tumor cells than in normal
cerebellum, but PTEN was found to be expressed at significantly lower levels in tumor cells compared with adjacent normal cerebellum. ML,
molecular layer of cerebellum; GCL, granule cell layer of cerebellum; TU, tumor. (Original magnification × 200).
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mors with high MI also had poorer prognosis than those
with low MI (P= 0.001) (Figure 3). Univariate analyses of
each factor with Cox log-rank analysis (Table 2) showed that
the other clinicopathological parameters, including meta-
static stage, histopathological subtype, and cell differentiation
were not significantly associated with tumor prognosis. In
multivariate analysis (Table 3), only high proliferative activity
(P= 0.001) and high DJ-1 expression (P= 0.009) in tumor
were independent predictors of OS for patients with MB.
MBs are a heterogenous group of highly malignant
embryonal brain tumors [20]. For many years, MBs have
been stratified into high-risk and standard-risk groups
according to age, metastatic stage at diagnosis, and ex-
tent of surgical resection. Standard-risk patients are
those diagnosed at ages over 3 years, have no metastases
at presentation, and have manageable residual tumor
(<1.5 cm2) after surgery. High-risk patients are those do
not fulfill these criteria [21], and these patients should
receive more intensive treatment. A recent study has
shown that the combination of chemotherapy and RT
has improved the 5-year survival rate, which is now 55%
to 76% for high-risk patients and 70% to 80% for standard-
risk patients [22]. However, in the present study, we found
that there was no significant difference in OS of patients
with different tumor risk, and tumor risk stratification was
not an independent factor for predicting the prognosis ofpatients with MB. The different treatment protocols based
on age stratification did not show any marked benefit for
prognosis. These results indicate that risk-adapted treat-
ments are not entirely suitable for all patients with MB.
Hence, it is important to identify novel clinical and
biological factors that can be used to predict treatment
response and accurately select patients who may bene-
fit from a more or less aggressive treatment, and to
improve risk stratification.
The importance of DJ-1 in the progression of MBs has
not been identified, although recent studies have demon-
strated that the DJ-1 molecule is relevant to the various
human tumors [20,23-25]. In the human brain, DJ-1 has
been observed in neurons [26] and non-neural cells [27].
DJ-1 has also been associated with autosomal recessive
early-onset parkinsonism, with loss of function of DJ-1
leading to neurodegeneration [28]. In gliomas, the rela-
tionship between high DJ-1 expression and high-grade
glioma has indicated that DJ-1 might play a role in the
acceleration of glioma progression [20]. In the current
study, we found the first evidence that high DJ-1 expres-
sion was closely correlated with undifferentiated tumor
and active proliferation of tumors. Survival analysis re-
vealed that high DJ-1 expression was significantly associ-
ated with low OS in patients with MB. Moreover, on
multivariate analysis, high DJ-1 expression emerged as an
independent factor influencing the prognosis of patients
Table 1 Correlation between proteins expression and clinicopathological characteristics of patients with MB
Clinicopathological
characteristics
DJ-1 expressiona p-Akt expressiona Proliferative activity
(Ki-67 value)bLow (n = 34) High (n = 32) Low (n = 29) High (n = 37)
Age, year
≤3 (n = 19) 13 6 7 12 25.28 ± 7.59
>3 (n = 47) 21 26 22 25 26.77 ± 8.74
P value 0.030 0.275 0.519
Sex
Male (n = 43) 23 20 18 25 25.80 ± 7.31
Female (n = 23) 11 12 11 12 27.36 ± 10.23
P value 0.619 0.527 0.475
WHO histological subtype c
Classic (n = 50) 23 27 22 28 25.17 ± 7.75
Desmoplastic (n = 14) 11 3 7 7 30.03 ± 9.89
P value 0.003 0.536 0.055
Tumor location
Fourth ventricle (n = 29) 16 13 10 19 26.65 ± 8.51
Outside fourth ventricle (n = 37) 18 19 19 18 26.11 ± 8.42
P value 0.556 0.065 0.795
Residual tumor size
≤1.5 cm2 (n = 54) 29 25 24 30 25.75 ± 8.14
>1.5 cm2 (n = 12) 5 7 5 7 29.04 ± 9.38
P value 0.221 0.829 0.222
Metastatic status
M0 (n = 12) 5 7 3 9 28.20 ± 7.39
M1 (n = 54) 29 25 26 28 25.93 ± 8.61
P value 0.221 0.007 0.401
Tumor risk
Standard (n = 6) 2 4 1 5 30.50 ± 9.58
High (n = 60) 32 28 28 32 25.93 ± 8.25
P value 0.031 0.010 0.201
Differentiation level
Undifferentiated (n = 39) 14 25 13 26 27.28 ± 8.82
Differentiated (n = 27) 20 7 16 11 25.00 ± 7.71
P value 0.001 0.007 0.281
DJ-1 expression
Low (n = 34) 20 14 23.33 ± 6.22
High (n = 32) 9 23 29.54 ± 9.28
P value 0.001 0.002
p-Akt expression
Low (n = 29) 20 9 25.13 ± 6.92
High (n = 37) 14 23 27.29 ± 9.38
P value 0.001 0.303
aχ2 test.
bOne-way ANOVA.
cWe did not carry out statistical analysis for the large cell/anaplastic variant and medullomyoblastoma because there were insufficient numbers of cases.
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Figure 3 Kaplan-Meier survival curves for DJ-1 expression and proliferative activity in tumor cells of MBs. Patients with MB with high
DJ-1 expression (left) or high MIB-1 index (right) had poorer OS.
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tumor progression and could be an independent prognos-
tic factor by influencing cell proliferation and differenti-
ation. To date, there is still no conclusive evidence that
measures of cell proliferation have clinical utility, and the
relevant studies have provided conflicting data. Some stud-
ies have shown an association between a simple evaluation
of mitotic count and survival for children with MB [29,30];
however, survival analyses do not support the use of the
Ki-67/MIB-1 index as prognostic indicator [31], although
high bromodeoxyuridine (BrdU) index (>20%) appeared to
indicated worse prognosis in one study [32]. In the present
study, high MIB-1 index had a strong correlation with poor
prognosis of patients with MB and may be an independent
indicator of tumor. More importantly, high proliferative ac-
tivity of tumor cells was associated with high expression of
DJ-1 protein. These data suggest that the cell proliferation
influencing the prognosis of patients with MB might be
modulated, at least partly, by the pathway involving the
DJ-1 molecule.
DJ-1 is considered to contribute to oncogenesis by up-
regulating PKB/Akt-mediated cell survival [6,11]. How-
ever, in this study, however, we did not find an association
between high p-Akt expression by tumor and high MIB-1
index of tumor cells, although high p-Akt expression was
observed to correlate closely with tumor differentiation
and metastasis.
Consistent with this result, p-Akt expression was not a
prognostic indicator for predicting the prognosis of pa-
tients with MB. On the one hand, activated Akt was
expressed at much higher levels in MB tumors compared
with normal human cerebellum, indicating that p-Akt
may be up-regulated in tumourigenesis and tumor pro-
gression of MBs, such as modulating tumor differentiation
and promoting metastasis. On the other hand, activated
Akt is an essential, but not the only, pathway in promoting
cell proliferation of MBs.
In addition, in the current study, we found that the
areas having high DJ-1 expression always overlapped
with those having p-Akt high expression.These results suggest that DJ-1 does indeed have a role
in modulating the Akt pathway in MBs, but it might not
be the only factor to influence activated Akt in tumor pro-
gression. Recent studies have demonstrated that several
growth factor receptors involving the PI3K/Akt cascade in
their signal transduction are expressed in MB, such as the
insulin-like growth factor-I receptor, Tropomyosin-related
kinase B (TrkB), Platelet-derived growth factor receptor-
beta (PDGFRB), and c-Kit [33-35]. PI3K/Akt signaling has
also been found to enhance the effects of Hedgehog in MB
tumor cells and their cerebellar precursors [36,37]. How-
ever, in the present study we did not detect co-expression
of DJ-1 and p-Akt in the same tumor cell, which would
have provided more direct evidence to elucidate their
relationship and cooperative effect on the modulation
of tumor progression. The precise mechanism of DJ-1,
p-Akt, and related growth factor receptors in the de-
velopment and progression of MBs will be investigated
in further studies.
PTEN is another key negative regulator of the PI3K
signaling pathway [38]. As MBs are known to display al-
lelic losses of chromosomal region 10q, where the PTEN
tumor suppressor gene is located, we hypothesize that
inactivation of PTEN could constitute a possible mech-
anism that might be responsible for Akt activation. Re-
cent data showed that losses of 10q are associated with
metastatic disease at diagnosis [39], and the PTEN mu-
tation detected in another study occurred only in a re-
current tumor that also carried a p53 mutation [40]. It
seems that the frequency of PTEN mutations is low in
MBs, and that mutation may be associated with a more
aggressive or relapsing phenotype of the tumor. In the
present study, we did not examine mutations of the
PTEN gene. However, we found that PTEN was inactivated
at the protein expression level. PTEN was significantly de-
creased in MB tumor cells compared with normal human
cerebellum, indicating that inactivation of PTEN at the
transcriptional level may also be involved in the regulation
of PTEN and thus may influence the activation of Akt. Epi-
genetic inactivation of PTEN has recently been reported in
Table 3 Cox regression model for multivariate analyses of






Age (≤3 years versus >3 years) 0.396 0.140 to 1.118 0.080
Gender (male versus female) 1.421 0.485 to 4.160 0.521
WHO histological subtype
(classic versus desmoplastic)
0.931 0.308 to 2.808 0.899
Tumor location (fourth ventricle
versus outside fourth ventricle)
1.201 0.404 to 3.573 0.741
Residual tumor size (≤1.5 cm2
versus >1.5 cm2)
0.391 0.139 to 1.102 0.075
Metastatic status (M0 versus M1) 1.720 0.310 to 9.546 0.534
Tumor risk (standard versus high) 0.695 0.041 to 11.92 0.802
Differentiation (differentiated
versus undifferentiated)
0.348 0.121 to 0.998 0.050
MIB-1 index (low versus high) 5.949 1.986 to17.814 0.001
DJ-1 expression (low versus high) 4.531 1.443 to14.223 0.009
p-Akt expression (low versus high) 0.765 0.217 to 2.698 0.678






95% CI, months P valuea
Age, year
≤ 3 44.96 ± 5.18 34.81 to 55.12 0.495
>3 47.72 ± 2.72 42.95 to 52.48
Sex
Male 47.16 ± 2.70 41.86 to 52.46 0.880
Female 46.60 ± 4.10 38.56 to 54.64
WHO histological
subtypeb
Classic 48.39 ± 2.41 43.66 to 53.12 0.263
Desmoplastic 41.39 ± 5.93 29.76 to 53.02
Tumor location
Fourth ventricle 46.35 ± 3.84 38.82 to 53.88 0.889
Outside fourth ventricle 47.66 ± 2.61 42.44 to 52.87
Residual tumor size
≤1.5 cm2 37.78 ± 6.14 25.73 to 45.83 0.052
>1.5 cm2 49.68 ± 2.28 45.19 to 54.16
Metastatic status
M0 42.08 ± 7.92 26.54 to 57.62 0.971
M1 47.45 ± 2.33 42.87 to 52.02
Tumor risk
Standard 46.64 ± 2.34 41.04 to51.24 0.062
High 23.75 ± 5.20 13.54 to33.95
Differentiation level
Undifferentiated 46.84 ± 3.03 40.89 to 52.79 0.823
Differentiated 46.87 ± 3.52 39.96 to 53.78
DJ-1 expression
Low 53.29 ± 1.79 49.77 to 56.81 0.007
High 40.28 ± 3.79 32.84 to 47.71
p-Akt expression
Low 47.76 ± 3.19 41.50 to 54.03 0.663
High 46.30 ± 3.23 39.97 to 52.63
aLog rank test.
bWe did not carry out statistical analysis for the large cell/anaplastic variant
and medullomyoblastoma because there were insufficient numbers of cases.
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tumors [41], but the related mechanisms of PTEN inactiva-
tion at the mRNA transcription level need to be clarified in
further investigations.
In the current study, we found that high DJ-1 expres-
sion was closely associated with classic MBs, and the
areas with high expression of DJ-1or p-Akt always coin-
cided with the regions that had loss of PTEN expression.
These regions were usually undifferentiated areas of clas-
sic MBs or internodular areas of desmoplastic MBs. How-
ever, expression of DJ-1 and p-Akt was decreased inintranodular areas of desmoplastic MBs, in which the tumor
cells appeared to have varying degrees of neuronal differenti-
ation. PTEN expression was also detectable in regions with
neuronal differentiation. Therefore, we hypothesize that
DJ-1and PTEN could modulate tumor cell differenti-
ation via Akt pathway. DJ-1 is due to its effects on the
PI3K signaling pathway, and may modulate PTEN func-
tion to produce hyperphosphorylation of Akt [6,11]. Re-
cent data have shown that PI3K/Akt signaling enhances
the effects of Hedgehog in MBs and their cerebellar pre-
cursors, and that it may represent an indispensable pre-
condition for the molecular realization of the Hedgehog
signal [36,37]. Inhibiting Hedgehog-dependent gene ex-
pression in MB can cause cell cycle arrest, consistent with
the initiation of neuronal differentiation and loss of neur-
onal stem cell-like characteristics [42]. Molecular analysis
has identified that the desmoplastic variant of MB is asso-
ciated with activation of the Hedgehog-Patched signaling
pathway [43]. The desmoplastic variant has been associ-
ated with a better prognosis than classic MB in some stud-
ies, although there is no significant difference in outcome
for these two variants in our study. Thus, the DJ-1/PTEN/
p-Akt/Hedgehog signaling system might play important
roles in modulating cell differentiation and further influ-
ence the outcome of MBs. Thus, blocking cell growth and
inducing cell differentiation in MBs by interfering with the
DJ-1 protein and Hedgehog pathway might represent a
novel approach to treat this tumor. In fact, some inhibi-
tors of the Hedgehog pathway, such as cyclopamine and
HhAntag, have been proven to cause the regression of
murine tumor allografts in vivo, and induce rapid death of
cells from freshly resected human MBs [44,45].
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Although the precise roles of DJ-1, PTEN and p-Akt in
MBs have not been identified, our study indicates links
between these molecules in their protein expression level
in MBs, and the validity of preliminary data in this study
needs to be confirmed by a larger number of cases. We
consider that DJ-1, PTEN, and p-Akt might play import-
ant roles in cell proliferation and differentiation of MBs,
and their expression levels might be useful parameters
for predicting the prognosis of patients with MB. Of
course, more rigorous investigations are necessary to
clarify their intrinsic links.
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